Bioventus BVS Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 68.7%+0.4pp | 68.3%+0.6pp | 67.8%+0.2pp | 67.6%+0.2pp | 67.4%-0.3pp | |
| Operating margin | 10%+0.5pp | 9.5%— | —— | —— | —— | |
| Net margin | 4.9%+0.9pp | 4%+2.7pp | 1.3%+1.5pp | -0.1%+5.8pp | -6%+0.3pp | |
| EBITDA margin | 18%+0.2pp | 17.8%+4.8pp | 13%+1.2pp | 11.8%+8.7pp | 3.1%0.0pp | |
| Free cash flow margin | 17.5%+4.8pp | 12.7%+3.2pp | 9.5%+3.4pp | 6%+1.8pp | 4.2%-2.4pp | |
| Returns | ||||||
| Return on equity | 16.9%+3.2pp | 13.7%+8.9pp | 4.8%+5.3pp | -0.5%+20.7pp | -21.2%+1.3pp | |
| Return on assets | 4.2%+1.0pp | 3.2%+2.2pp | 1%+1.1pp | -0.1%+4.5pp | -4.6%+0.1pp | |
| Return on invested capital | 12.3%+0.4pp | 11.9%+6.7pp | 5.2%+1.7pp | 3.5%+9.6pp | -6.1%+0.2pp | |
| Efficiency | ||||||
| Asset turnover | 0.9×+0.1× | 0.8×0.0× | 0.8×0.0× | 0.8×0.0× | 0.8×0.0× | |
| Inventory turnover | 2×0.0× | 2.1×+0.1× | 2×0.0× | 2×+0.1× | 1.9×-0.1× | |
| Liquidity | ||||||
| Current ratio | 1.7×0.0× | 1.7×0.0× | 1.7×+0.3× | 1.5×+0.1× | 1.4×+0.1× | |
| Quick ratio | 1.1×-0.1× | 1.2×0.0× | 1.1×+0.2× | 1×+0.1× | 0.9×0.0× | |
| Cash ratio | 0.2×-0.1× | 0.3×+0.1× | 0.3×+0.1× | 0.2×0.0× | 0.1×-0.1× | |
| Leverage | ||||||
| Debt-to-equity | 1.5×-0.2× | 1.7×-0.4× | 2.1×-0.2× | 2.2×-0.2× | 2.5×+0.1× | |
| Debt-to-assets | 0.4×0.0× | 0.5×0.0× | 0.5×0.0× | 0.5×0.0× | 0.5×0.0× | |
| Net debt / EBITDA | 2.4×-0.1× | 2.6×-1.5× | 4.1×-0.8× | 4.9×-14.5× | 19.5×+1.6× | |
| Per Share | ||||||
| Book value per share | $2.70+1.0% | $2.67+10.7% | $2.41+2.6% | $2.35+4.8% | $2.24-2.1% | |
| Valuation | ||||||
| Market capitalization | $659.19M+51.7% | $498.3M+11.4% | $447.51M-0.2% | $448.58M-25.9% | $605.34M-11.8% | |
| Enterprise value | $911.76M+17.2% | $758.41M+1.6% | $746.51M-3.8% | $776.32M-18.2% | $948.66M-5.2% | |
| Price / earnings | 23.1×— | 21.9×-37.0× | 59×— | —— | —— | |
| Price / sales | 1.1×+0.4× | 0.9×+0.1× | 0.8×0.0× | 0.8×-0.3× | 1.1×-0.1× | |
| Price / book | 3.5×+0.6× | 2.7×0.0× | 2.7×-0.1× | 2.8×-1.3× | 4.1×-0.6× | |
| EV / EBITDA | 8.8×-35.4× | 7.5×-2.7× | 10.2×-1.5× | 11.7×-42.1× | 53.8×-3.0× | |
| EV / sales | 1.6×+0.2× | 1.3×0.0× | 1.3×-0.1× | 1.4×-0.3× | 1.7×-0.1× | |
| Free cash flow yield | 15.3%+9.8pp | 14.5%+2.5pp | 11.9%+4.3pp | 7.6%+3.6pp | 4%-1.6pp | |
| Earnings yield | 4.3%+12.1pp | 4.6%+2.9pp | 1.7%+1.9pp | -0.2%+5.4pp | -5.6%-0.3pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Bioventus's profit margins?
- Bioventus (BVS) runs a 68.7% gross margin and a 10.0% operating margin, with a 4.9% net margin.
- Where do Bioventus's ratios come from?
- Every ratio is computed from Bioventus's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
